rechARge: a randomized phase III trial of the androgen receptor ligand-directed degrader, BMS-986365, vs investigator's choice in patients with mCRPC.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
960 patients will be enrolled.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Approximately 960 patients will be enrolled. www.clinicaltrials.gov identifier is NCT06764485.
There is an ongoing need for efficacious, life-prolonging therapies for males with metastatic castration-resistant prostate cancer (mCRPC).
APA
Chi KN, McKay RR, et al. (2025). rechARge: a randomized phase III trial of the androgen receptor ligand-directed degrader, BMS-986365, vs investigator's choice in patients with mCRPC.. Future oncology (London, England), 21(14), 1771-1777. https://doi.org/10.1080/14796694.2025.2502318
MLA
Chi KN, et al.. "rechARge: a randomized phase III trial of the androgen receptor ligand-directed degrader, BMS-986365, vs investigator's choice in patients with mCRPC.." Future oncology (London, England), vol. 21, no. 14, 2025, pp. 1771-1777.
PMID
40455815 ↗
Abstract 한글 요약
There is an ongoing need for efficacious, life-prolonging therapies for males with metastatic castration-resistant prostate cancer (mCRPC). mCRPC that progresses after treatment with androgen receptor pathway inhibitors (ARPIs) may still be driven by AR signaling. BMS-986365 is a heterobifunctional, orally bioavailable ligand-directed degrader that targets the AR through a first-in-class dual mechanism of AR degradation and antagonism. Here, we present the study design of rechARge, a phase III, randomized, multicenter, adaptive, two-part, open-label trial evaluating BMS-986365 versus investigator's choice of therapy comprising either docetaxel or a switch to an alternative ARPI (abiraterone or enzalutamide) in patients with mCRPC whose disease has progressed after treatment with one prior ARPI. The primary study objective is to compare the efficacy and safety of BMS-986365 versus investigator's choice of therapy. Approximately 960 patients will be enrolled. www.clinicaltrials.gov identifier is NCT06764485.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
- Humans
- Male
- Androgen Receptor Antagonists
- Androstenes
- Benzamides
- Clinical Trials
- Phase III as Topic
- Docetaxel
- Multicenter Studies as Topic
- Nitriles
- Phenylthiohydantoin
- Prostatic Neoplasms
- Castration-Resistant
- Randomized Controlled Trials as Topic
- Receptors
- Androgen
- Treatment Outcome
- Adaptive Clinical Trials as Topic
- BMS‑986365
- androgen receptor
- clinical trial
- ligand-directed degrader
- metastatic castration resistant prostate cancer
- phase III
… 외 2개
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.
- Early local immune activation following intra-operative radiotherapy in human breast tissue.